CNC

Business profile & competitive position

Centene Corp. operates in the Healthcare sector under the Medical – Healthcare Plans industry. It describes itself as the nation’s largest managed-care company focused on underserved populations, delivering Medicaid, Medicare Advantage, Prescription Drug Plans, Medicare Supplement, and commercial Marketplace coverage through local brands supported by national infrastructure. Beyond traditional medical benefits, Centene connects members with supports such as food, housing, utilities, and transportation.

The company’s scale is substantial: 2025 total revenues were $194.8 billion, with 57% from Medicaid, 21% from Commercial, 19% from Medicare, and 3% from Other. As of December 31, 2025, membership stood at 27.6 million, including 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. Centene is also the largest Medicaid insurer, largest Marketplace insurer, and largest stand-alone PDP provider in the United States. In December 2025 it signed a definitive agreement to divest the remaining Magellan Health businesses, suggesting continued portfolio shaping.

That scale, however, does not automatically translate into profitability in the current snapshot. Net margin is -2.6% and return on equity is -24.0%. Those figures imply that the company’s low-cost, high-volume model is currently under margin pressure and that equity capital is earning a negative trailing return. The competitive moat—size, local-market density, and government-program specialization—exists, but its value is being tested by recent bottom-line losses.

Financial posture

Centene’s current market capitalization is $32.8 billion, and the stock trades at a P/E of -6.4. A negative P/E simply means reported earnings are negative; the multiple is therefore not a useful valuation yardstick on its own. With $194.8 billion in 2025 revenue, the market cap represents a small fraction of annual sales, which is consistent with a managed-care business producing near-term losses while retaining a very large top line.

Net margin of -2.6% and ROE of -24.0% confirm that the most recent earnings profile is stressed. At the same time, operating cash flow in 2025 was $5.1 billion, so cash generation remains materially positive despite the GAAP loss. Beta is 1.11, indicating the stock has moved slightly more than the broad market. The snapshot price is $66.40, RSI is 53.5, and the 50-day exponential moving average sits at $64.35, placing the current price just above that short-term smoothing level.

Strategic priorities & outlook

Centene’s most recent 10-K emphasizes several near-term operational priorities. The company plans to continue refining its Medicare footprint so that it overlaps more closely with its Medicaid operations, while expanding Dual Eligible Special Needs Plans (D-SNP) as a long-term growth driver. Management is also prioritizing enterprise-wide D-SNP integration, aligning products with CMS requirements that take effect through 2030.

On the commercial side, Centene intends to implement 2026 corrective Marketplace pricing actions in states covering 95% of its Marketplace membership and to expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states. The filing also notes ongoing advocacy for policies that preserve affordable Medicaid and Marketplace coverage and cost-effective care for PDP members.

The divestiture of the remaining Magellan Health businesses is another notable theme, potentially simplifying the organization and freeing management bandwidth. In short, the stated strategy mixes growth in D-SNP and Marketplace correction with regulatory alignment and portfolio cleanup.

Macro & geopolitical exposure

Because Centene sits in the Medical – Healthcare Plans industry, its most relevant macro exposures are regulatory and fiscal rather than commodity or currency driven. Medicaid spending depends on state budgets and federal matching formulas, while Medicare Advantage, PDP, and Marketplace plans are tied to CMS reimbursement rates, benefit rules, medical-loss-ratio requirements, and star-rating methodologies.

Changes in administration, legislation, or state Medicaid expansion decisions can alter membership eligibility and profitability quickly. Healthcare utilization trends, pharmaceutical pricing policy, and broader cost inflation also flow directly into managed-care earnings. The sector is less exposed to tariffs or raw-material supply chains than industrials or manufacturers, but it is highly exposed to rule changes, reimbursement cuts, and state or federal budget priorities.

Recent developments

The most recent headline mentions are sparse on company-specific events. On September 14, 2026, Zacks included Centene in a list titled “Best Growth Stocks to Buy for September 14th.” A similar Zacks feature, “Best Growth Stocks to Buy for September 10th,” appeared on September 10. On September 9, Zacks also listed CNC among “5 Broker-Loved Stocks to Bet on Amid the Current Chaotic Scenario.” These are stock-screen or thematic mentions, not operational news.

The one concrete business headline on September 9, 2026, came from PR Newswire: “Fill the Gap: More Affordable Homes on the Way for Stanislaus County Residents thanks to Health Net's $2 Million Investment.” Health Net is one of Centene’s local brands, and the item illustrates the company’s community-investment activity rather than a material financial event.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Centene has beaten earnings expectations seven times, for an 88% beat rate, with an average earnings surprise of 63.1%. The average five-day price move in the trading sessions following those reports has been +2.83%, classified as an upward post-earnings drift.

The last four quarters show how messy the headline reaction can be even when estimates are beaten. On July 28, 2026, Centene reported EPS of $2.51 against an estimate of $1.09—a 130.3% surprise—but the stock fell 3.27% the next day and gained only 0.25% over the following five sessions. On April 28, 2026, EPS of $3.37 versus $2.23 (a 51.1% surprise) produced an 8.9% next-day pop and a 6.88% five-day gain. The February 6, 2026 report, with EPS of -$1.19 versus -$1.22007 (a 2.5% surprise), led to a -1.09% one-day drop but a +5.51% five-day drift. The October 29, 2025 quarter delivered a 445.4% surprise with EPS of $0.50 versus -$0.14475, yet the stock fell 6.21% the next day and drifted -1.34% over five sessions.

The next scheduled report is October 27, 2026, before the open, with a consensus EPS estimate of $0.07. That estimate is low relative to the prior four actual results, and the post-earnings drift history is upward on average—but individual post-earning price paths have been inconsistent.

For a fuller picture of how sell-side analysts, insider activity, and institutional holders are positioned ahead of the October 27 report, readers should consult the complete institutional verdict rather than relying on a single headline metric.